147 related articles for article (PubMed ID: 17108015)
1. Iris atrophy in patients with newly diagnosed multibacillary leprosy: at diagnosis, during and after completion of multidrug treatment.
Daniel E; Sundar Rao PS; Ffytche TJ; Chacko S; Prasanth HR; Courtright P
Br J Ophthalmol; 2007 Aug; 91(8):1019-22. PubMed ID: 17108015
[TBL] [Abstract][Full Text] [Related]
2. Incidence of ocular morbidity among multibacillary leprosy patients during a 2 year course of multidrug therapy.
Daniel E; Ffytche TJ; Sundar Rao PS; Kempen JH; Diener-West M; Courtright P
Br J Ophthalmol; 2006 May; 90(5):568-73. PubMed ID: 16622085
[TBL] [Abstract][Full Text] [Related]
3. Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy.
Daniel E; Ffytche TJ; Kempen JH; Rao PS; Diener-West M; Courtright P
Br J Ophthalmol; 2006 Aug; 90(8):949-54. PubMed ID: 16707521
[TBL] [Abstract][Full Text] [Related]
4. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
Kaur I; Dogra S; Kumar B; Radotra BD
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
6. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
8. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
9. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
Dasananjali K; Schreuder PA; Pirayavaraporn C
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
[TBL] [Abstract][Full Text] [Related]
10. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
[TBL] [Abstract][Full Text] [Related]
11. Fixed-duration multidrug therapy in multibacillary leprosy.
Li HY; Hu LF; Wu PW; Luo JS; Liu XM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
[TBL] [Abstract][Full Text] [Related]
12. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up.
Richardus JH; Nicholls PG; Croft RP; Withington SG; Smith WC
Int J Epidemiol; 2004 Apr; 33(2):337-43. PubMed ID: 15082636
[TBL] [Abstract][Full Text] [Related]
13. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
14. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
15. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in epidemiological factors associated with treatment completion status of leprosy patients in the most hyperendemic district of Nepal.
Kumar RB; Singhasivanon P; Sherchand JB; Mahaisavariya P; Kaewkungwal J; Peerapakorn S; Mahotarn K
Southeast Asian J Trop Med Public Health; 2004 Jun; 35(2):334-9. PubMed ID: 15691132
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
18. Preliminary assessment of multidrug therapy in leprosy patients in Western Samoa.
Paksoy N; Levi V
N Z Med J; 1989 Nov; 102(879):589-91. PubMed ID: 2812597
[TBL] [Abstract][Full Text] [Related]
19. Impairments in multibacillary leprosy; a study from Brazil.
Pimentel MI; Nery JA; Borges E; Gonçalves RR; Sarno EN
Lepr Rev; 2004 Jun; 75(2):143-52. PubMed ID: 15282965
[TBL] [Abstract][Full Text] [Related]
20. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):250-8. PubMed ID: 10575404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
